Keywords
nuclear medicine
oncology
radiopharmaceuticals
therapy
How to Cite
Abstract
Radiopharmaceuticals are drugs that typically consist of a radioisotope and a ligand or some type of a biological carrier. Applications of radiopharmaceuticals include diagnostic imaging, therapy, and, ultimately, the emerging field of Theranostics. This article summarizes the current state of knowledge regarding the use of radiopharmaceuticals in oncology.
References
[1] Fahey F, Grant F. Celebrating eighty years of radionuclide therapy and the work of Saul Hertz. J Appl Clin Med Phys 2021;22:4-10.
[2] Ehrhardt JD Jr, Güleç S. A review of the history of radioactive iodine theranostics: the origin of nuclear ontology. Mol Imaging Radionucl Ther. 2020;29(3):88-97.
[3] Varghese T, John A, Mathew J. Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy. Precis Radiat Oncol 2024;8:145-152.
[4] Gillings N, Hjelstuen O, Ballinger J, Behe M, Decristoforo C, Elsinga P i in. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem 2021;6:8.
[5] Zhang S, Wang X, Gao X, Chen X, Li L, Li G i in. Radiopharmaceuticals and their applications in medicine. Signal Transduct Target Ther 2025;10(1):1.
[6] Trägårdh M, Møller N, Sørensen M. Methodologic considerations for quantitative 18F-FDG PET/CT studies of hepatic glucose metabolism in healthy subjects. J Nucl Med. 2015;56:1366-1371.
[7] Patching SG. Roles of facilitative glucose transporter GLUT1 in [¹⁸F]FDG positron emission tomography (PET) imaging of human diseases. J Diagn Imaging Ther 2015;2:30-102.
[8] Wang Y, Shao G, Wu J, Cui C, Zang S, Qiu F i in. Preparation of 68Ga‑PSMA‑11 with a Synthesis Module for Micro PET‑CT Imaging of PSMA Expression during Prostate Cancer Progression. Contrast Media Mol Imaging 2018;2018:8046541.
[9] Cacko M, Jóźwik‑Plebanek K, Wnuk J, Teresińska A. Incidental finding of [99mTc]Tc‑MIBI uptake in a post‑radiotherapy breast without recurrence of cancer. Nucl Med Rev Cent East Eur 2023;26(0):156‑157.
[10] Hofman MS, Iravani A. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. PET Clin 2017;12:219-234.
[11] Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T i in. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19:825-833.
[12] Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M i in. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med 2020;45(1):19-31.
[13] Sun Y-Q, Sun D, Zhang X, Zhang Y-Q, Lin Y-S. Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration. Front Endocrinol (Lausanne) 2022;13:994288.
[14] Das S, Al-Toubah T, El-Haddad G, Strosberg J i in. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumours. Expert Rev Gastroenterol Hepatol 2019;13(11):1023-1031.
[15] Bolcaen J, Kleynhans J, Nair S, Verhoeven J, Goethals I, Sathekge M i in. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma. Theranostics 2021;11(16):7911-7947.
[16] Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F i in. An overview of targeted alpha therapy with 225 Ac and 213 Bi. Curr Radiopharm 2018;11(3):200-208.
[17] Ku A, Facca VJ, Cai Z, Reilly RM i in. Auger electrons for cancer therapy — a review. EJNMMI Radiopharm Chem 2019;4(1):27.
[18] Monfared YK, Heidari P, Klempner SJ, Mahmood U, Parikh AR, Hong TS i in. DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair. Pharmaceutics 2023;15(12):2761.
[19] European Directorate for the Quality of Medicines & HealthCare. Guide for the elaboration of monographs on radiopharmaceutical preparations. Strasbourg: EDQM; 2018.
[20] Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci 2023;24:11626.
[21] Westerbergh F, van der Meulen NP, Müller C, Grings A, Ritt P, Bernhardt P. Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls. EJNMMI Res 2025;15(1):13.
[22] Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H i in. 225Ac-PSMA-617/ 177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging 2020;47:721-728.
[23] Cheng Z, Chen P, Yan J. A review of state-of-the-art resolution improvement techniques in SPECT imaging. EJNMMI Phys 2025;12:9.
[24] Alberts I, Sari H, Mingels C, Afshar-Oromieh A, Pyka T, Shi K i in. Long-axial field-of-view PET/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients. Cancer Imaging 2023;23:28.
[25] Schaefferkoetter J, Shah V, Hayden C, Prior JO, Zuehlsdorff S. Deep learning for improving PET/CT attenuation correction by elastic registration of anatomical data. Eur J Nucl Med Mol Imaging 2023;50:2292-2304.
[26] Olin AB, Hansen AE, Rasmussen JH, Jakoby B, Berthelsen AK, Ladefoged CN i in. Deep learning for Dixon MRI-based attenuation correction in PET/MRI of head and neck cancer patients. EJNMMI Phys 2022;9:20.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2026 Letters in Oncology Science